Synthetic DNA of Unlimited Length
Ribbon Biolabs raises 18 M EUR Series A Financing
Next level DNA synthesis
Ribbon Biolabs revolutionary technology for the fast and efficient automated synthesis of DNA is here to enable the new wave of biotechnological innovation.
Through our unique technology combining biochemistry, computing and automation, Ribbon Biolabs will make complex DNA accessible and affordable for our customers in the biotech industry and in academia.
Ribbon Biolabs wants to place itself as the key player in synthetic DNA of any complexity, empowering its customers to tackle challenges and develop products that today are only possible in our imagination.
A breakthrough in DNA synthesis
By synthesising DNA molecules longer than 10.000 basepairs, Ribbon Biolabs hits a major milestone that goes beyond the present technological capabilities for the de novo synthesis fo DNA and redefines the current industry standards.
These achievements prove the capability and the potential of Ribbon Biolabs’ in-house synthesis platform InfiniSynth, a technology involving machine-learning and robotic automation for the enzymatic assembly of long DNA molecules.
Accelerate your R&D
We make synthetic DNA of any length available for your innovative application in biotechnology, biopharma or academic research. Whether you need long DNA molecules or variant libraries – with our radically novel technology, you will have it at hand in only days and at affordable cost.
Invest in the future of biotech
Synthetic biology is not only one of the most rapidly growing markets, it also has disruptive potential. The major bottleneck for its advance is the availability of synthetic DNA. Ribbon Biolabs’ cost-efficient platform for automated high-throughput production of long and complex DNA molecules will help to overcome this impediment.
Invest in the future of biotech
Synthetic biology is one of the most rapidly growing markets and has disruptive potential for many industries. The major bottleneck for its advance is the availability of synthetic DNA. Ribbon Biolabs’ platform for automated high-throughput production of long DNA will help to overcome this impediment.
Join our team
As an early-stage startup company with ambitious growth plans we are always looking for talented people to expand our diverse and interdisciplinary team. Besides a workplace in one of the most liveable cities of the world and a new state-of-the art laboratory we offer the opportunity to grow with the company.
News and Events
Apr. 12, 2022
Meet us at SynBioBeta Conference!
After a couple of years of online meetings, we’ll join this year’s Global Synthetic Biology Conference on April 12-13 LIVE in Oakland!
Jan 31, 2022
Ribbon Biolabs raises 18 M EUR Series A Financing enabling commercial scale production facilities and US expansion for DNA synthesis technology.
Today the company announced the successful close of its Series A funding round from a consortium of European and US investors led by Hadean Ventures …
May 21, 2021
Ribbon Biolabs successfully synthesises a 10 kbp DNA molecule using their FullGenes platform
The DNA Synthesis company Ribbon Biolabs announces the achievement of a key technology milestone, underlining its capability and potential …
May 19, 2021
Meet us at SynBioBeta BioPharma!
For the first time ever, SynBioBeta is hosting a special, one-day special on all hot topics in biopharma. We are looking forward to meeting you there …
Apr 19, 2021
Ribbon Biolabs’ Advisory Board member Eörs Szathmary elected to Norwegian Academy of Sciences
Prof. Eörs Szathmary of Eötvös University in Hungary has been elected to the Humanities and Social Sciences section of the Norwegian Academy of Sciences and Letters …